{
    "id": "dbpedia_8100_2",
    "rank": 30,
    "data": {
        "url": "https://www.pharmaceutical-technology.com/data-insights/borneol-edaravone-simcere-pharmaceutical-group-net-present-value/",
        "read_more_link": "",
        "language": "en",
        "title": "Risk adjusted net present value: What is the current valuation of Simcere Pharmaceutical Group’s (Borneol + edaravone)?",
        "top_image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2022/01/cropped-Pharmaceutical-Technology-Favicon-150x150.png",
        "meta_img": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2022/01/cropped-Pharmaceutical-Technology-Favicon-150x150.png",
        "images": [
            "https://www.facebook.com/tr?id=1175064750058523&ev=PageView&noscript=1",
            "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2017/09/PHT-1.png",
            "https://www.mining-technology.com/wp-content/uploads/sites/19/2023/01/globaldata_logo-1.png",
            "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2017/09/desktop_Model_RHS.png",
            "https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/icons/offsite.png'",
            "https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/icons/offsite.png'",
            "https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/gd-Logo-pi.svg",
            "https://www.mining-technology.com/wp-content/uploads/sites/19/2023/01/globaldata_logo-1.png",
            "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2017/09/desktop_Model_RHS.png",
            "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/shutterstock_2476637021-e1723819184658.jpg",
            "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/shutterstock_2061290192.jpg",
            "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/Liver-1024x576.jpg",
            "https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/icons/catfish-icon.svg",
            "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2017/09/PharmaceuticalTechnology_footer.png",
            "https://www.pharmaceutical-technology.com/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/linkedin_icon_w.svg",
            "https://www.pharmaceutical-technology.com/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/twitter_icon_w.svg",
            "https://www.pharmaceutical-technology.com/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/facebook_icon_w.svg",
            "https://www.pharmaceutical-technology.com/code/wp-content/themes/goodlife-wp-B2B/assets/images/verdict-logo-w.png",
            "https://analytics.twitter.com/i/adsct?txn_id=ocdmp&p_id=Twitter&tw_sale_amount=0&tw_order_quantity=0",
            "https://t.co/i/adsct?txn_id=ocdmp&p_id=Twitter&tw_sale_amount=0&tw_order_quantity=0"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "kgi-admin"
        ],
        "publish_date": "2023-06-30T07:35:53+00:00",
        "summary": "",
        "meta_description": "(Borneol + edaravone) is a small molecule commercialized by Simcere Pharmaceutical Group, with a leading Phase I program in Acute Ischemic Stroke.",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "Pharmaceutical Technology",
        "canonical_link": "https://www.pharmaceutical-technology.com/data-insights/borneol-edaravone-simcere-pharmaceutical-group-net-present-value/",
        "text": "The revenue for (Borneol + edaravone) is expected to reach an annual total of $7 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.\n\n(Borneol + edaravone) Overview\n\nDexborneol and Edaravone (Sanbexin) is a fixed dose combination product, acts as a cerebro protective agent. Sanbexin is indicated for the improvement of neurological symptoms and dysfunction of activities of daily living caused by acute cerebral infarction. It is under development for the treatment of acute ischemic stroke, amyotrophic lateral sclerosis and Intracerebral hemorrhage. It acts by targeting free radical. The drug candidate is administered through sublingual route as a tablet and through parenteral route.\n\nSimcere Pharmaceutical Group Overview\n\nSimcere Pharmaceutical Group (Simcere) discovers, develops and markets branded generic and prescription pharmaceutical products. The company’s product therapeutic areas include anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle and others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low-end generics and APIs for innovative medicines. Simcere is headquartered in Nanjing, Jiangsu, China.\n\nThe company reported revenues of (Renminbi) CNY6,607.8 million for the fiscal year ended December 2023 (FY2023), an increase of 4.5% over FY2022. In FY2023, the company’s operating margin was 10.8%, compared to an operating margin of 13.6% in FY2022. In FY2023, the company recorded a net margin of 10.8%, compared to a net margin of 14.7% in FY2022.\n\nFor a complete picture of (Borneol + edaravone)’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.\n\nThis content was updated on 10 June 2024"
    }
}